Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a clinical-stage biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. It operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. Its technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. Its development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants. AEROSURF is an investigational combination drug/device product that combines its KL4 surfactant with aerosol delivery system (ADS).